Ritter Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2019
31 mars 2020 17h27 HE
|
Ritter Pharmaceuticals, Inc.
Definitive merger agreement with Qualigen, Inc. announced in January 2020 LOS ANGELES, March 31, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”,...
Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement
21 janv. 2020 09h15 HE
|
Ritter Pharmaceuticals, Inc.
Transaction to Create a Nasdaq-listed Biotechnology Company Focused on Advancing Qualigen’s Cancer and Infectious Disease Therapeutic Development Programs LOS ANGELES, Jan. 21, 2020 (GLOBE...
Ritter Pharmaceuticals Provides Phase 3 Liberatus Clinical Trial and Regulatory Update
20 juin 2019 09h15 HE
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, June 20, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate...
Ritter Pharmaceuticals Reports Year End 2018 Financial Results and Provides Business Update
29 mars 2019 09h00 HE
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, March 29, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of therapeutic products that modulate the gut...
Citius Provides Update on Its CITI Platforms and Gives Investors Further Insight on their Licensing Agreement with MD Anderson Cancer Center
06 févr. 2019 13h11 HE
|
The Wall Street Analyzer
NEW YORK, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Citius Pharmaceuticals, Inc.’s (NASDAQ: CTXR) CEO, Myron Holubiak recently caught up with The Wall Street Analyzer to update investors on the companies’...
Ritter Pharmaceuticals Announces Appointment of Andrew J. Ritter as Chief Executive Officer
27 juin 2018 07h05 HE
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, June 27, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate...
Ritter Pharmaceuticals Initiates First Pivotal Phase 3 Trial for RP-G28 for the Treatment of Lactose Intolerance
27 juin 2018 07h00 HE
|
Ritter Pharmaceuticals, Inc.
Conference Call Today - June 27, 2018 at 4:30 p.m. ET LOS ANGELES , June 27, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a...
Mount Tam Biotechnologies Announces that the European Patent Office Has Allowed a Key Patent for Lead Compound TAM-01
22 févr. 2018 09h00 HE
|
Mount Tam Biotechnologies Inc.
NOVATO, CA , Feb. 22, 2018 (GLOBE NEWSWIRE) -- Mount Tam Biotechnologies, Inc. ("Mount Tam") (OTC PINK: MNTM), a company focused on the discovery and development of novel mTOR inhibitors, is pleased...